A detailed history of Voya Investment Management LLC transactions in Scholar Rock Holding Corp stock. As of the latest transaction made, Voya Investment Management LLC holds 45,234 shares of SRRK stock, worth $2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
45,234
Previous 45,492 0.57%
Holding current value
$2 Million
Previous $378,000 4.23%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$7.63 - $9.71 $1,968 - $2,505
-258 Reduced 0.57%
45,234 $362,000
Q2 2024

Dec 03, 2024

BUY
$7.84 - $16.79 $2,022 - $4,331
258 Added 0.57%
45,492 $378,000
Q2 2024

Aug 14, 2024

SELL
$7.84 - $16.79 $561,626 - $1.2 Million
-71,636 Reduced 61.16%
45,492 $378,000
Q1 2024

Dec 06, 2024

BUY
$13.2 - $17.76 $949,000 - $1.28 Million
71,894 Added 158.94%
117,128 $2.08 Million
Q1 2024

May 15, 2024

BUY
$13.2 - $17.76 $1.25 Million - $1.69 Million
94,950 Added 428.13%
117,128 $2.08 Million
Q4 2023

Feb 14, 2024

BUY
$6.52 - $20.32 $27,325 - $85,161
4,191 Added 23.3%
22,178 $416,000
Q3 2023

Nov 14, 2023

BUY
$6.02 - $7.76 $39,292 - $50,649
6,527 Added 56.95%
17,987 $127,000
Q2 2023

Aug 14, 2023

BUY
$5.79 - $9.11 $66,353 - $104,400
11,460 New
11,460 $86,000
Q2 2022

Aug 15, 2022

SELL
$4.66 - $13.96 $51,604 - $154,593
-11,074 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$24.14 - $35.18 $144 - $211
6 Added 0.05%
11,074 $275,000
Q2 2021

Aug 16, 2021

SELL
$26.34 - $46.62 $4,109 - $7,272
-156 Reduced 1.39%
11,068 $320,000
Q1 2021

May 17, 2021

BUY
$45.96 - $68.02 $15,304 - $22,650
333 Added 3.06%
11,224 $569,000
Q4 2020

Feb 16, 2021

BUY
$13.72 - $51.57 $149,424 - $561,648
10,891 New
10,891 $529,000

Others Institutions Holding SRRK

About Scholar Rock Holding Corp


  • Ticker SRRK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,640,600
  • Market Cap $2.28B
  • Description
  • Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clini...
More about SRRK
Track This Portfolio

Track Voya Investment Management LLC Portfolio

Follow Voya Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.